Content area

Abstract

Williams syndrome (WS) is a relatively rare microdeletion disorder that occurs in as many as 1:7,500 individuals. WS arises due to the mispairing of low-copy DNA repetitive elements at meiosis. The deletion size is similar across most individuals with WS and leads to the loss of one copy of 25–27 genes on chromosome 7q11.23. The resulting unique disorder affects multiple systems, with cardinal features including but not limited to cardiovascular disease (characteristically stenosis of the great arteries and most notably supravalvar aortic stenosis), a distinctive craniofacial appearance, and a specific cognitive and behavioural profile that includes intellectual disability and hypersociability. Genotype–phenotype evidence is strongest for ELN, the gene encoding elastin, which is responsible for the vascular and connective tissue features of WS, and for the transcription factor genes GTF2I and GTF2IRD1, which are known to affect intellectual ability, social functioning and anxiety. Mounting evidence also ascribes phenotypic consequences to the deletion of BAZ1B, LIMK1, STX1A and MLXIPL, but more work is needed to understand the mechanism by which these deletions contribute to clinical outcomes. The age of diagnosis has fallen in regions of the world where technological advances, such as chromosomal microarray, enable clinicians to make the diagnosis of WS without formally suspecting it, allowing earlier intervention by medical and developmental specialists. Phenotypic variability is considerable for all cardinal features of WS but the specific sources of this variability remain unknown. Further investigation to identify the factors responsible for these differences may lead to mechanism-based rather than symptom-based therapies and should therefore be a high research priority.

Williams syndrome is a rare genetic disorder caused by the microdeletion of a region of chromosome 7q11.23. In this Primer, Pober and colleagues provide an overview of the epidemiology, genetic aetiology, diagnosis, common manifestations and management of this syndrome as well as of how quality of life is affected in individuals with Williams syndrome and their families.

Details

Title
Williams syndrome (Primer)
Author
Kozel, Beth A 1 ; Barak Boaz 2 ; Kim, Chong Ae 3   VIAFID ORCID Logo  ; Mervis, Carolyn B 4   VIAFID ORCID Logo  ; Osborne, Lucy R 5 ; Porter, Melanie 6 ; Pober, Barbara R 7 

 Translational Vascular Medicine Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, USA (GRID:grid.279885.9) (ISNI:0000 0001 2293 4638) 
 Tel Aviv University, The Sagol School of Neuroscience and The School of Psychological Sciences, Tel Aviv, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546) 
 Universidade de São Paulo, Department of Paediatrics, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722) 
 University of Louisville, Department of Psychological and Brain Sciences, Louisville, USA (GRID:grid.266623.5) (ISNI:0000 0001 2113 1622) 
 University of Toronto, Department of Medicine, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938) 
 Macquarie University, Department of Psychology, Sydney, Australia (GRID:grid.1004.5) (ISNI:0000 0001 2158 5405) 
 Massachusetts General Hospital and Harvard Medical School, Department of Paediatrics, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
2056676X
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2542128407
Copyright
© Springer Nature Limited 2021.